FMC Corporation reports second quarter 2026 results with Adjusted EBITDA above high end of guidance range and solid cash generation
FMC Corporation (NYSE: FMC) reported Q2 2026 revenue of $867 million, down 17% year over year, and Adjusted EBITDA of $153 million. GAAP net loss was $187 million, or $1.49 per diluted share. Cash from operations rose to $363 million. FMC lowered full-year 2026 guidance, including revenue excluding India to $3.50-$3.70 billion and Adjusted EBITDA to $620-$680 million.
How this was made
The 30-second read
Why it matters
Q2 results show strong cash from operations and a stated Adjusted EBITDA beat versus guidance range, while the company simultaneously lowered full-year revenue, EBITDA, and EPS ranges due to a more challenging macro environment and planned Rynaxypyr pricing actions.
Market read
Traders can reassess FMC’s near-term earnings trajectory using the updated full-year ranges and the specific cash and financing actions that support leverage reduction.
What to watch
Debt-reduction proceeds and the India business sale, property sale-leaseback, and Tessenderlo equity investment are subject to closing conditions and regulatory approvals, which can delay balance-sheet relief.
Background
FMC completed a strategic review and is executing four operational pillars, including debt reduction and managing the post-patent transition for Rynaxypyr.
Ticker impact
FMC reported Q2 2026 results and raised/updated full-year outlook, with Adjusted EBITDA above the high end of guidance and free cash flow strength.
Likely positive near-term bias, with follow-through dependent on whether investors focus on EBITDA beat versus the lowered full-year revenue and EPS ranges.
The article provides concrete Q2 datapoints (Adjusted EBITDA $153M, cash from ops $363M) and specific updated full-year ranges, plus defined debt-reduction proceeds and licensing/corporate actions that affect balance-sheet risk.
Market effects
Signals continued pressure in parts of the crop-input market (lower diamide partner orders, legacy product demand) while growth portfolio offsets partially.
Highlights North America weakness tied to strained grower margins and order timing shifts into later quarters.
FX is described as a low-single digit tailwind, implying currency effects remain a key swing factor for reported performance.
Counterpoint
The headline EBITDA strength may not offset the broader downshift in full-year revenue, Adjusted EBITDA, and Adjusted EPS, so the market may still de-rate the stock on earnings power.
Key entities
- companyFMC Corporation
Reported Q2 2026 results, updated full-year guidance, and outlined debt-reduction proceeds including an India business sale, rimisoxafen licensing upfront payment, a property sale-leaseback, and a Tessenderlo equity investment.
- companyCorteva
Partner in the rimisoxafen licensing agreement referenced for a $200 million upfront payment.
- companyTessenderlo Group
Agreed to a $400 million equity investment referenced as part of FMC’s targeted debt-reduction proceeds.
